Holen Sie sich die Stockscreener-App
1.878
6.03%
-0.112
Schlusskurs vom Vortag:
$1.99
Offen:
$2.04
24-Stunden-Volumen:
373.35K
Relative Volume:
0.34
Marktkapitalisierung:
$384.75M
Einnahmen:
$889.00K
Nettoeinkommen (Verlust:
$-156.28M
KGV:
-3.5656
EPS:
-0.5267
Netto-Cashflow:
$-150.06M
1W Leistung:
-8.33%
1M Leistung:
+3.89%
6M Leistung:
-22.73%
1J Leistung:
+208.33%
1-Tages-Spanne:
$1.86
$2.04
1-Wochen-Bereich:
$1.86
$2.206
52-Wochen-Spanne:
$1.02
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.875 | 416.56M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
520.62 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.35 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.52 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.40 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Value Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Value Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Index - marketscreener.com
Price to earnings forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to earnings forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Price to sales forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to revenue forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Enterprise value to EBITDA forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to sales forward of ProKidney Corp. Class A – BMV:PROK - TradingView
ProKidney Corp (PROK) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProKidney Corp. Class A Actuals & Estimates (NASDAQ:PROK) - TradingView
ProKidney Corp. (PROK) Faces Selling Pressure Near Resistance – Key Levels in FocusDouble EMA - dars.gov.et
PROK Forecast — Price Target — Prediction for 2027 - TradingView
ProKidney (PROK) Study Update Summary - Quartr
ProKidney Corp (PROK) Institutional Confidence - TradingKey
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProKidney Corp (PROK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PROK Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path - Yahoo Finance
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stock - Stock Titan
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrow EPS Beat Amid Clinical ProgressOperating Margin Analysis - newsline.com
[Form 3] PROKIDNEY CORP. Initial Statement of Beneficial Ownership - Stock Titan
Identiv And Two Other Penny Stocks To Watch Closely - simplywall.st
PROK: Phase III cell therapy for advanced CKD targets dialysis delay, with pivotal data due in 2027 - TradingView
ProKidney appoints Kenneth Locke as chief technical officer - The Pharma Letter
ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout - The Business Journals
ProKidney expands executive management team with chief technical officer - Winston-Salem Journal
Prokidney Corp. Announces Appointment of Kenneth Locke as Chief Technical Officer - marketscreener.com
ProKidney names Kenneth Locke as chief technical officer By Investing.com - Investing.com Australia
ProKidney Corp. Appoints Kenneth Locke as Chief Technical Officer - geneonline.com
ProKidney names Kenneth Locke as chief technical officer - Investing.com
ProKidney Appoints Kenneth Locke as Chief Technical Officer - The Manila Times
ProKidney shareholders reaffirm board and auditor at 2026 meeting - The Globe and Mail
PROKIDNEY CORP. (PROK) director receives 135,000 stock options grant - Stock Titan
Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation - Stock Titan
ProKidney (PROK) director receives 135,000 stock options grant as compensation - Stock Titan
ProKidney (PROK) director awarded 135K stock options as compensation - Stock Titan
ProKidney (NASDAQ: PROK) grants 135,000 stock options to director - Stock Titan
[Form 4] PROKIDNEY CORP. Insider Trading Activity - Stock Titan
PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award - Stock Titan
ProKidney (NASDAQ: PROK) 2026 meeting backs board nominees and EY - Stock Titan
ProKidney Corp. (PROK) Edges Higher Amid Continued Support: Potential for Breakout Above $1.94 ResistanceCombination Correction - The Legal Advocate
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prokidney Corp-Aktie (PROK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
0.82%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):